ATE410414T1 - Heteroarylacryloylaminoalkyl-substituierte benzolsulfonamidderivate, deren herstellung, deren verwendung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten - Google Patents

Heteroarylacryloylaminoalkyl-substituierte benzolsulfonamidderivate, deren herstellung, deren verwendung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten

Info

Publication number
ATE410414T1
ATE410414T1 AT01992700T AT01992700T ATE410414T1 AT E410414 T1 ATE410414 T1 AT E410414T1 AT 01992700 T AT01992700 T AT 01992700T AT 01992700 T AT01992700 T AT 01992700T AT E410414 T1 ATE410414 T1 AT E410414T1
Authority
AT
Austria
Prior art keywords
compounds
preparation
cardiac
heteroarylacryloylaminoakyl
benzenesulfonamide derivatives
Prior art date
Application number
AT01992700T
Other languages
English (en)
Inventor
Holger Heitsch
Heinrich Englert
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE410414T1 publication Critical patent/ATE410414T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01992700T 2000-11-03 2001-10-20 Heteroarylacryloylaminoalkyl-substituierte benzolsulfonamidderivate, deren herstellung, deren verwendung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten ATE410414T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10054482A DE10054482A1 (de) 2000-11-03 2000-11-03 Heteroarylacryloylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
ATE410414T1 true ATE410414T1 (de) 2008-10-15

Family

ID=7662010

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992700T ATE410414T1 (de) 2000-11-03 2001-10-20 Heteroarylacryloylaminoalkyl-substituierte benzolsulfonamidderivate, deren herstellung, deren verwendung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten

Country Status (13)

Country Link
US (1) US6472413B2 (de)
EP (1) EP1335902B1 (de)
JP (1) JP4281991B2 (de)
AT (1) ATE410414T1 (de)
AU (2) AU2002223631B2 (de)
CA (1) CA2427548C (de)
DE (2) DE10054482A1 (de)
DK (1) DK1335902T3 (de)
ES (1) ES2315314T3 (de)
IL (2) IL155658A0 (de)
MX (1) MXPA03003778A (de)
PT (1) PT1335902E (de)
WO (1) WO2002036565A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956846B2 (en) * 2002-08-16 2005-10-18 Utstarcom Incorporated System and method for foreign agent control node redundancy in a mobile internet protocol network

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1493672C3 (de) * 1964-08-01 1974-05-02 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1518874C3 (de) 1964-10-07 1975-03-13 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe und Verfahren zu ihrer Herstellung
DE1518816C3 (de) 1965-03-24 1975-05-22 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4066639A (en) 1965-05-06 1978-01-03 Hoechst Aktiengesellschaft Benzene-sulfonyl semicarbazides and process for preparing them
DE59401361D1 (de) 1993-02-23 1997-02-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe- Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika
DE4341655A1 (de) 1993-12-07 1995-06-08 Hoechst Ag Aminosubstituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika
DE19505397A1 (de) 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832009A1 (de) * 1998-07-16 2000-01-20 Hoechst Marion Roussel De Gmbh 2,5-Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharamazeutische Präparate
HK1040187B (zh) 1998-09-10 2005-09-02 萨诺费-阿文蒂斯德国有限公司 苯磺酰(硫)脲與β-受體阻滯劑聯合在製備用於心臟迷走神經機能障礙治療和預防的藥物中的用途
DE19923086A1 (de) * 1999-05-20 2000-11-23 Aventis Pharma Gmbh Cinnamoylaminoalkyl-substituierte Benzolsulfonamidderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
JP2004513114A (ja) 2004-04-30
DE60136088D1 (de) 2008-11-20
AU2002223631B2 (en) 2006-07-06
AU2363102A (en) 2002-05-15
JP4281991B2 (ja) 2009-06-17
IL155658A (en) 2010-04-15
CA2427548C (en) 2010-11-16
IL155658A0 (en) 2003-11-23
MXPA03003778A (es) 2003-07-28
DE10054482A1 (de) 2002-05-08
US20020123495A1 (en) 2002-09-05
WO2002036565A1 (en) 2002-05-10
ES2315314T3 (es) 2009-04-01
PT1335902E (pt) 2009-01-19
US6472413B2 (en) 2002-10-29
DK1335902T3 (da) 2009-02-16
EP1335902B1 (de) 2008-10-08
EP1335902A1 (de) 2003-08-20
CA2427548A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
DE60109324D1 (de) Acylaminoalkyl-substituierte benzolsulfonamidderivate
WO2003048164A3 (en) Adenosine a2a receptor antagonists
DD279407A1 (de) Verfahren zur herstellung eines mittels gegen aids
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
DE68906609D1 (de) Dopamin-vorlaeufer.
EP0977570A1 (de) Chinoxaline in dreier-kombination mit proteaseinhibitoren und reverse transkriptaseinhibitoren als arzneimittel zur behandlung von aids
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
DE60136088D1 (de) Heteroarylacryloylaminoalkyl-substituierte benzolsulfonamidderivate, deren herstellung, deren verwendung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten
WO2000003978A3 (de) 2,5-substituierte benzolsulfonylharnstoffe und -thioharnstoffe, v,rfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
CA2534833A1 (en) Bicyclo[3.1.1]heptane substituted benzimidazolone and quinazoli-none derivatives as agonists on human orl1 receptors
HUT55633A (en) Process for producing pharmaceutical compositions containing pyrimidinyl-piperazine derivatives for treating depression
MX2009012644A (es) Derivados de di(hetero)arilciclohexano, su preparacion, su uso y composiciones farmaceuticas que los comprenden.
IL183807A0 (en) Piperidinesulfonylureas and-thioureas, their preparation, their use and pharmaceutical compositions comprising them
ITMI931723A1 (it) Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
MEP41508A (en) Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives
IL159767A0 (en) Sulfonamide derivatives, their preparation and pharmacetuical compositions containing them
WO2025188658A8 (en) Akt1 modulators
MX9606397A (es) Cromanilsulfonil(tio)ureas sustituidas, procedimientos para prepararlas, y su utilizacion en preparados farmaceuticos, asi como preparados farmaceuticos que las contienen.
CA2270026A1 (en) Substituted bicyclic derivatives for treating central nervous system disorders
DE19961302A1 (de) Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
DE3831949A1 (de) Arzneimittel
CA2534558A1 (en) Ammonium salts of ornithine derivatives for treating inflammatory diseases
MX9708783A (es) 3-amido-cromanilsulfonil (tio) ureas, procedimiento para su preparacion, su empleo y preparados farmaceuticos que las contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1335902

Country of ref document: EP